Sun Pharma Q2 PAT seen down 54.7% to Rs 1139 cr: Centrum

Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 8.3 percent Y-o-Y) to Rs 7407 crore, according to Centrum.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Earnings » Brokerage Results Estimates

Oct 19, 2016, 04.01 PM | Source: Moneycontrol.com

Sun Pharma Q2 PAT seen down 54.7% to Rs 1139 cr: Centrum

Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 8.3 percent Y-o-Y) to Rs 7407 crore, according to Centrum.

Like this story, share it with millions of investors on M3

Sun Pharma Q2 PAT seen down 54.7% to Rs 1139 cr: Centrum

Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 8.3 percent Y-o-Y) to Rs 7407 crore, according to Centrum.

Post Your Comments

Share Cancel

| 1 Comments

Centrum Broking (more)

, Centrum Broking |

Centrum has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Sun Pharma  to report net profit at Rs 1139 crore, down 54.7 percent quarter-on-quarter.

Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 8.3 percent Y-o-Y) to Rs 7407 crore, according to Centrum.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 32.3 percent Q-o-Q (up 2.2 percent Y-o-Y) to Rs 1977 crore.

Centrum's report on Sun Pharma

We expect Sun Pharma Industries (SPIL) to report revenue growth of 8% YoY and decline of 10% QoQ to Rs74.07bn. We expect the domestic business (26% of revenues) to grow by 7% YoY to Rs 19.50bn from Rs 18.19bn.

Its US formulation business (46% of revenues) is likely to grow by 2% YoY to Rs 33.80bn from Rs 33.16bn due to lower growth of Taro, pricing pressure in the US market and consolidation of distributors in the US. Emerging markets (14% of revenues) are expected to grow by 13% YoY to Rs 10.30bn from Rs 9.09bn. 

The net profit is likely to grow by 3% YoY to Rs 11.39bn from Rs 11.07bn due to slower revenue growth and decline in margins.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Buy, Hold, Sell ? Hear it first on M3
Sun Pharma Q2 PAT seen down 54.7% to Rs 1139 cr: Centrum

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login